RT Journal Article
SR Electronic
T1 Leveraging mathematical models of disease dynamics and machine learning to improve development of novel malaria interventions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.05.21249283
DO 10.1101/2021.01.05.21249283
A1 Golumbeanu, Monica
A1 Yang, Guojing
A1 Camponovo, Flavia
A1 Stuckey, Erin M.
A1 Hamon, Nicholas
A1 Mondy, Mathias
A1 Rees, Sarah
A1 Chitnis, Nakul
A1 Cameron, Ewan
A1 Penny, Melissa A.
YR 2022
UL http://medrxiv.org/content/early/2022/03/14/2021.01.05.21249283.abstract
AB Background Substantial research is underway to develop next-generation interventions that address current malaria control challenges. As there is limited testing in their early development, it is difficult to predefine intervention properties such as efficacy that achieve target health goals, and therefore challenging to prioritize selection of novel candidate interventions. Here, we present a quantitative approach to guide intervention development using mathematical models of malaria dynamics coupled with machine learning. Our analysis identifies requirements of efficacy, coverage, and duration of effect for five novel malaria interventions to achieve targeted reductions in malaria prevalence. This study highlights the role of mathematical models to support intervention development.Methods A mathematical model of malaria transmission dynamics is used to simulate deployment and predict potential impact of new malaria interventions by considering operational, health-system, population, and disease characteristics. Our method relies on consultation with product development stakeholders to define the putative space of novel intervention specifications. We couple the disease model with machine learning to search this multi-dimensional space and efficiently identify optimal intervention properties that achieve specified health goals. We demonstrate the power of our approach by application to five malaria interventions in development.Results Aiming for malaria prevalence reduction, we identify and quantify key determinants of intervention impact along with their minimal properties required to achieve the desired health goals. While coverage is generally identified as the largest driver of impact, higher efficacy, longer protection duration or multiple deployments per year are needed to increase prevalence reduction. We show that the efficacy and duration needs depend on the biological action of the interventions. Interventions on multiple parasite or vector targets, as well as combinations the new interventions with drug treatment, lead to significant burden reductions and lower efficacy or duration requirements.Conclusions Our approach uses disease dynamic models and machine learning to support decision-making and resource investment, facilitating development of new malaria interventions. By evaluating the intervention capabilities in relation to the targeted health goal, our analysis allows prioritization of interventions and of their specifications from an early stage in development, and subsequent investments to be channeled cost-effectively towards impact maximization. Although we focus on five malaria interventions, the analysis is generalizable to other new malaria interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Foundation (OPP1170505 to MAP) and the Swiss National Science Foundation (PP00P3_170702 to MAP)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicableI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the analysis code used in the paper as well as corresponding documentation, parameterizations and configuration files for the software workflow necessary to generate the simulation data with OpenMalaria and reproduce the analysis are available at https://github.com/SwissTPH/TPP_workflow. https://github.com/SwissTPH/TPP_workflow